Abstract
Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram.
Highlights
Relapsing chronic and neurological Lyme disease with persistent infection despite treatment is well-documented and problematic [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]
It has been suggested that co-infection with Lyme disease and babesiosis may result in more severe disease expression [35]
Disulfiram was identified as a highly active compound against borrelia in vitro, after screening 7450 drug molecules from different chemical libraries [36,38]. This finding suggests that United States Food & Drug Administration FDA-approved disulfiram might have the potential to treat Lyme disease in humans
Summary
Relapsing chronic and neurological Lyme disease with persistent infection despite treatment is well-documented and problematic [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]. Disulfiram was identified as a highly active compound against borrelia in vitro, after screening 7450 drug molecules from different chemical libraries [36,38]. This finding suggests that United States Food & Drug Administration FDA-approved disulfiram might have the potential to treat Lyme disease in humans. Disulfiram, unexpectedly, appeared to exert activity against borreliosis and babesiosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
